Highlights Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Market Closed - Nasdaq Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
0.72 ^USD	+10.09%		+15.74%	-32.11%

06-10	BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO	MT
05-15	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
North American Morning Briefing : S&P 500 Futures -2-	03-05	DJ
Reverse Split: 1 of 15	01-31	FA
Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Alaunos Therapeutics Announces Exploration of Strategic Alternatives	14/08/23	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	14/08/23	CI
Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies	29/06/23	CI
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting	25/05/23	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Precigen, Inc. Announces Amendment of Its Exclusive License Agreement with Alaunos Therapeutics, Inc	03/04/23	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	07/03/23	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	07/03/23	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022	14/11/22	CI
Alaunos Therapeutics, Inc. Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference	21/09/22	CI
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using Its TCR-T Cell Therapy	06/09/22	CI
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference	24/08/22	CI
Alaunos Therapeutics Q2 Loss Narrows -- Shares Rise	15/08/22	MT
Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022	15/08/22	CI
Alaunos Therapeutics, Inc. and National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025	27/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Highlights

Filters